Multi-platform lung tumors profiling identifies actionable targets and unveils series of uncommon/rare diseases.
Lung cancer is characterized by a number of genetic alterations, of which a proportion is still unknown. Nevertheless numerous pathogenetically important driver changes have been already been detected in a substantial fraction of patients and translated into a system to improve detection and outcome of the disease. In this scenario, the Lung Cancer Mutation Consortium developed an ambitious project aimed to perform on large scale the molecular profile of lung adenocarcinoma in order to identify actionable targets. The review analyses the paper - recently published showing study findings- taking into account if the car and not the driver matters in lung cancer precision management.